Story perspectives

Blood Test Predicts Treatment Success in Breast Cancer

1/19/2026

40 3

Summary

Story summary

The Institute of Cancer Research, London reported that a blood test measuring circulating tumor DNA (ctDNA) can predict treatment responses in advanced breast cancer.
Researchers analyzed ctDNA from 167 patients at treatment start and after four weeks.
In triple-negative breast cancer patients, low ctDNA yielded 10.2 months progression-free survival versus 4.4 months for higher ctDNA.
The findings suggest ctDNA could serve as a non-invasive biomarker for monitoring treatment effectiveness.

1 of 1

Story summary

The Institute of Cancer Research, London reported that a blood test measuring circulating tumor DNA (ctDNA) can predict treatment responses in advanced breast cancer.
Researchers analyzed ctDNA from 167 patients at treatment start and after four weeks.
In triple-negative breast cancer patients, low ctDNA yielded 10.2 months progression-free survival versus 4.4 months for higher ctDNA.
The findings suggest ctDNA could serve as a non-invasive biomarker for monitoring treatment effectiveness.